MedTrace Logo

A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy

NCT01561755 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-04-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.

Conditions

  • HIV-associated Myelopathy

Interventions

DRUG

Intravenous Immunoglobulin

Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®

DRUG

Placebo

Placebo - 2gr/kg over 2 days of saline

Sponsors & Collaborators

  • CSL Behring

    collaborator INDUSTRY

  • David M. Simpson

    lead OTHER

Principal Investigators

  • David Simpson, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01561755 on ClinicalTrials.gov